Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had between 4 and 10 migraine days per month with moderate to severe pain in each of the 3 months before your first study visit (this still applies if you are on preventive migraine treatment that has reduced your migraines into this range).
- You are currently prescribed and have been taking ubrogepant for at least 3 months to treat your migraines, as approved by the FDA.
- You are an adult who has been officially diagnosed with migraine or chronic migraine according to recognised medical guidelines.
Who may not be able to join:
- You are currently taking part in another clinical or non-interventional research study.
- You are taking a type of medication known as a "strong CYP3A4 inhibitor" — these are certain drugs that can affect how other medicines are processed by the body (confirm with trial site if you are unsure whether any of your medications fall into this category).
- You have been diagnosed with certain other headache conditions, including new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus, or painful cranial neuropathy (confirm with trial site if you are unsure whether your diagnosis falls into one of these categories).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants with Absence of moderate to severe headache over 24 hours post-dose during prodrome.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.